AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic treatment Botox. Now, the companies have extended their dominance to the ...

The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective therapies from AbbVie and Grace Therapeutics. For AbbVie, the Chicago drugmaker had ...

AbbVie says Congress excluded Botox from price controls Lawsuit alleges multiple constitutional violations Botox contributes over 10% to AbbVie's annual revenue HHS declines to comment Feb 12 (Reuters ...

AbbVie has sued the Department of Health and Human Services (HHS), challenging the agency’s decision to select its blockbuster anti-wrinkle therapy Botox for the next round of Medicare price ...